NEW YORK, Aug. 30, 2017 -- The Law Offices of Vincent Wong announce that a securities action has been commenced on behalf of investors who purchased Blue Apron Holdings, Inc. ("Blue Apron") (NYSE:APRN) securities pursuant and/or traceable to the Company’s Initial Public Offering on or about June 29, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sbm/blue-apron-holdings-inc?wire=3. There is no cost or obligation to you.
The complaint filed in this class action alleges that Blue Apron violated the Securities Act of 1934 because the Registration Statement failed to disclose that: (1) rather than continue to significantly increase spending on advertising, Blue Apron had already decided to significantly reduce spending on advertising in Q2 2017, which would hurt sales and profit margins in future quarters; (2) Blue Apron was already experiencing adverse on-time in-full rates, meaning orders were not arriving on time or with all the ingredients needed, which was hurting customer retention; and (3) the Company had run into delays in Q2 2017 with its new factory in Linden, New Jersey.
If you suffered a loss in Blue Apron contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sbm/blue-apron-holdings-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]


Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Italy Fines Apple €98.6 Million Over App Store Dominance
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement 



